Want to see SABS full AI Analyst Report?
Top Page
SAB Biotherapeutics
(NASDAQ:SABS)
Select Model
Select Model
Rating:53Neutral
Price Target:
$4.00
▲(13.96% Upside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by weak financial performance—near-zero recent revenue and substantial ongoing cash burn despite a low-debt balance sheet. Technicals add some support with the stock trading above key moving averages and neutral RSI, while valuation appears low (P/E ~8.3) but is discounted due to business traction and cash-flow concerns.
Positive Factors
Proprietary antibody platform
SAB’s Tc bovine platform is a differentiated technology base for generating fully human polyclonal antibodies. If validated clinically, it can support multiple programs and partnerships, creating platform-level opportunity beyond any single candidate.
Negative Factors
Revenue collapse
The collapse to effectively zero revenue shows that SAB lacks dependable commercial or partnership revenue at present. Without recovery through collaborations, grants, or product approvals, the company remains dependent on external funding and future clinical success.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary antibody platform
SAB’s Tc bovine platform is a differentiated technology base for generating fully human polyclonal antibodies. If validated clinically, it can support multiple programs and partnerships, creating platform-level opportunity beyond any single candidate.
Read all positive factors
SAB Biotherapeutics (SABS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$343.02M
Dividend YieldN/A
Average Volume (3M)398.22K
Price to Earnings (P/E)3.0
Beta (1Y)0.96
Revenue Growth-100.00%
EPS Growth95.16%
CountryUS
Employees86
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.24
Shares Outstanding90,986,370
10 Day Avg. Volume357,955
30 Day Avg. Volume398,221
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)0.48
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside241.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.14
Revenue Forecast (FY)N/A
SAB Biotherapeutics Business Overview & Revenue Model
Company Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product ca...
How the Company Makes Money
SAB Biotherapeutics makes money primarily through (1) collaboration and partnership revenue and (2) other sources such as grants or similar non-dilutive funding when applicable; product sales revenue is typically null or immaterial while the compa...
SAB Biotherapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 1.32M | 2.24M | 23.90M | 60.88M |
| Gross Profit | -2.28M | -3.08M | -3.47M | -1.51M | 20.61M | 59.22M |
| EBITDA | -9.46M | 16.60M | -28.99M | -38.13M | -15.12M | -15.20M |
| Net Income | -12.78M | 13.27M | -34.11M | -42.19M | -18.74M | -17.14M |
Balance Sheet | ||||||
| Total Assets | 238.21M | 172.81M | 44.20M | 83.94M | 50.90M | 81.14M |
| Cash, Cash Equivalents and Short-Term Investments | 102.63M | 96.59M | 20.76M | 56.57M | 15.05M | 33.21M |
| Total Debt | 5.13M | 5.95M | 4.67M | 5.91M | 5.93M | 8.52M |
| Total Liabilities | 23.43M | 21.32M | 18.23M | 26.64M | 19.85M | 42.59M |
| Stockholders Equity | 214.78M | 151.49M | 25.97M | 57.30M | 31.06M | 38.55M |
Cash Flow | ||||||
| Free Cash Flow | -72.70M | -45.71M | -34.63M | -25.32M | -25.63M | -8.96M |
| Operating Cash Flow | -68.21M | -44.78M | -34.29M | -25.12M | -23.46M | 1.99M |
| Investing Cash Flow | -267.75M | -121.71M | -11.96M | -152.70K | -2.09M | -10.94M |
| Financing Cash Flow | 350.85M | 168.30M | -1.17M | 66.77M | 1.05M | 35.89M |
SAB Biotherapeutics Risk Analysis
SAB Biotherapeutics disclosed 88 risk factors in its most recent earnings report. SAB Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SAB Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $90.28M | 2.14 | 68.56% | ― | -15.11% | ― | |
53 Neutral | $343.02M | 3.04 | -6.74% | ― | -100.00% | 95.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $35.29M | -0.73 | -175.46% | ― | ― | 59.14% | |
41 Neutral | $9.73M | -0.66 | -101.90% | ― | -90.65% | 26.48% |
* Healthcare Sector Average
SABS
SAB Biotherapeutics
3.79
1.79
89.50%
LSTA
Lisata Therapeutics
1.15
-1.35
-54.00%
NXTC
NextCure
6.65
1.56
30.65%
RLYB
Rallybio
16.77
12.22
268.41%
SAB Biotherapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial
Positive
Jul 7, 2026
On July 7, 2026, SAB Biotherapeutics and Breakthrough T1D announced that Breakthrough T1D has awarded a grant to support PRISE-hATG, a randomized, double-blind, placebo-controlled clinical study of SAB-142 in Stage 3 type 1 diabetes patients 100 d...
Executive/Board ChangesShareholder Meetings
SAB Biotherapeutics Shareholders Back Board and Auditor
Positive
Jun 18, 2026
On June 18, 2026, SAB Biotherapeutics held its 2026 Annual Meeting of Stockholders, where approximately 76.12% of the common shares entitled to vote were represented, ensuring a quorum. Shareholders elected four Class II directors—Dr. David ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.